Trial Profile

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine IMA202-101)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMA-202 (Primary) ; Interleukin-2
Indications Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms ACTengine; ACTengine IMA202-101
Sponsors Immatics US

27 Apr 2023 Status changed from active, no longer recruiting to completed.
27 Jun 2022 Status changed from recruiting to active, no longer recruiting.
23 Mar 2022 According to an Immatics media release, patient recruitment in the dose escalation part of the Phase 1 trial has been completed and dose escalation is ongoing.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com